WA
ORMP icon

WealthTrust-Arizona’s Oramed Pharmaceuticals ORMP Stock Holding History

WealthTrust-Arizona’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-500
Closed -$3K – 610
2016
Q1 		$3K Buy
+500
New +$3.35K ﹤0.01% 511

Other funds holding ORMP

TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
FANJ
Financial Architects (New Jersey) Marlton, New Jersey $663M AUM 15.53% 1-Year Est. Return

WealthTrust-Arizona's ORMP Position: Q2 2016 in Review

WealthTrust-Arizona sold out of Oramed Pharmaceuticals (ORMP) in Q2 2016, closing a stake of 500 shares — an estimated $3K sold.

WealthTrust-Arizona first reported a position in ORMP in Q1 2016 and held it in 1 quarter. The position peaked at $3K in Q1 2016. 25 funds tracked by Wall St. Rank hold ORMP as of Q2 2016.

  • WealthTrust-Arizona reported no remaining Oramed Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • WealthTrust-Arizona sold 500 Oramed Pharmaceuticals shares in Q2 2016, an estimated $3K.
  • WealthTrust-Arizona first reported a position in Oramed Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • WealthTrust-Arizona's Oramed Pharmaceuticals position peaked at $3K in Q1 2016.
  • 25 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2016.

Based on WealthTrust-Arizona's 13F filing for Q2 2016, filed 20 Jul 2016.